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NEUROHUMORS IN THE BRAIN**
About 25 years ago, after Loewi had produced simple, direct and con-
vincing evidence for chemical transmission at neuro-effector junctions in
the heart and Dale had provided similar evidence for the neuromuscular
junction, Sir Charles Sherrington made it clear that he had foreseen the
possibility of chemical transmission at synapses in the central gray matter.
At that time (1935) Sherrington told Dale: "I have always assumed that
the process at the motor nerve ending must provide a model, or paradigm,
for that at the central synapse.'
At first it was natural to inquire simply whether acetylcholine (ACh)
is the central transmitter. Today, in the face of renewed and vigorous
investigation in this area, the available evidence will not allow us to assume
that ACh is the universal central synaptic transmitter, but it does suggest
that ACh is a mediator at numerous central synapses. This is not to say,
moreover, that the state of our knowledge is satisfactory and unambiguous.
The most decisive evidence for chemical transmission, i.e., the collection
and identification of the transmitter after stimulation of the presynaptic
neurone, and the demonstration that the presumed transmitter when
applied exogenously can elicit characteristic postsynaptic responses, has
not been obtained for any specific central synapse. It is worth consider-
ing Paton's view that the pharmacological evidence now accepted for cen-
tral chemical transmission is often weak,'M but the situation is by no means
unpromising.
The design of experiments, the construction of working hypotheses, and
general thinking concerning this problem owe a great deal to the wealth
of data available on humoral transmission at such peripheral sites as auto-
nomic ganglia, secretory cells, smooth and skeletal muscles. The peri-
pheral findings, however, can only have relevance to events in the central
nervous system (CNS) when viewed in the light of data coming directly
from the CNS itself; and only recently have such data been forthcoming
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in any abundance. Nevertheless, there has been a noticeable lack of re-
straint on the part of investigators lately to ascribe the role of central
transmitter to several of the recently discovered natural products of the
nervous system without presenting adequate experimental evidence for
such a role.
We owe a great deal to Feldberg's clear thinking and careful exposi-
tion having dispelled some of the confusion in this area. In keeping with
some of his ideas and with those put forward more recently by Elkes,'
one can establish some minimal criteria which should be met by any nat-
urally occurring substance to be entertained for a role as a chemical trans-
mitter at central synapses.
1. The first of these is that the substance should be present in the CNS,
not in a uniform, but rather in a discreet pattern of distribution. If the
substance is to be considered a transmitter and not merely a neuroregula-
tory hormone, it should be ascertained that it is elaborated in the neurone
and released from the presynaptic nerve terminal. Furthermore, it is to
be expected that local concentrations of the substance will be shown to be
related to the function of a given neural structure, and that fluctuation in
local concentration will take place in response to functioning of such a
structure, or will lead to a quantitative change in the function of the
structure.
2. Secondly, there should be in the CNS enzymatic mechanisms for
the synthesis of the material, and enzymatic or other mechanisms for its
destruction and the dissipation of its action. Such mechanisms necessarily
should involve reactions of high velocity, consonant with the rapidity of
events in the nervous system. Synthesis need not keep pace with demand,
however, if provisions are available for storage of the material in an inactive
form.
3. Thirdly, there should be clearly demonstrable effects resulting from
a deliberate increase or decrease in the local concentration of the sub-
stance. Such a change can be brought about in one of two ways. One can
alter the concentration in the brain directly by applying the substance
topically to the brain or by administering it into the vascular system. The
brain level can also be altered indirectly by the systematic administration
of a known metabolic precursor of the substance or of an inhibitor of the
destructive enzyme. In all three cases, the administration of the substance
itself, its precursor, or the inhibitor of the destructive enzyme, a consid-
eration of the blood-brain barrier enters prominently. It must be ascer-
tained that the appropriate compounds can traverse this barrier.
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4. Finally, known blocking agents of the substance should also pro-
duce demonstrable effects by virtue of prevention of the transmitter from,
access to its specific receptor sites.
Largely because of currently productive investigations of chemical sub-
stances which alter mood and behavior in man, there has been a resurgence
of interest in chemical transmission in the brain. As an outgrowth of this
intensive research, has come, in the past few years, an elucidation of the-
nature of a number of interesting new substances in brain, most of which
have been suggested as possible transmitter substances. These include some
new esters of choline related to ACh, an amine, 5-hydroxytryptamine
TABLE 1. LEVEL OF ACH IN RAT'S BRAIN DURING VARIOUS STAGES
OF CNS ACTIVITY*
Functional state
of CNS ACh Content (,ug./gm.)
Deep anesthesia
(barbiturate and ether) 1.8 3.9 5.8 5.5
Sleep 1.4 ... ...
Normal 1.3 2.9 3.5 3.0
Excitement 0.9 ...
Convulsions 0.6 2.2 2.9
Richter and Tobias Elliott Wajda'
Crossland' etal.7" et al.4
* Adapted from Feldberg.'
(5-HT, serotonin), which must be added to epinephrine, nor-epinephrine,
and histamine as biogenic amines with potential neurohumoral function,
and at least one polypeptide, substance P.
ACETYLCHOLINE
It is perfectly natural to turn one's attention first to the peripheral
synaptic transmitter, ACh, about which a tremendous body of information
has accumulated. To be sure, ACh is present in the CNS in a non-
random distribution; and its concentration does vary with the functional
state of the CNS (Table 1).
Apart from the inconsistency in absolute values, which no doubt result
from differences in technique of extraction and bioassay, it is possible to
see certain trends in the relative values: high levels of ACh seem to obtain
during states of CNS depression, while lower levels appear during wakeful-
ness. An important problem which must be met in such studies is whether
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there is a causal relationship between the level of the chemical in the brain
and the functional state observed. Does the rise in ACh precede and lead to
sleep and anesthesia or does the depressed brain cause some imbalance in the
dynamic relationship among synthesis of ACh, its storage, its release, and
its destruction? Actually, rates of change in concentration of the transmitter
would be more revealing than absolute or relative values at any given
moment.
There is no longer any doubt about the close relation between electrical
activity in the cortex, ACh content, and release of ACh from this area.
However, this relationship with respect to frank seizures is apparently a
complex one. Richter and Crossland' have demonstrated an unusual phasic
association of ACh content with convulsive activity. Electrical stimulation
produced first a sharp decline in ACh content of the brain followed by a
return to almost normal levels before convulsions supervened. Since the
time intervals in these experiments were in the order of 10-20 seconds, a
massive synthesis, or more probably a massive release, of ACh must be
assumed to have taken place.'
This brings up a point of importance which applies as well to the CNS
as to the peripheral nervous system. Because the transmitter must be a
highly reactive chemical and must take part in high velocity reactions, it
most probably exists in a pre-formed pool which is held away from the
receptor sites (and destructive enzymes) either by protein binding or by
anatomic barriers (e.g., intracellular granules). Tower and Elliott79 have
drawn attention to the importance of distinguishing between free and
"bound" ACh, and have emphasized the probable role played by ionic
forces in regulating the release of ACh from its storage sites. Recently,
intracellular granules have been shown to serve as depots for ACh,a cate-
cholamines," histamine,' and 5-HT."'
It is now definitely established by the work of Nachmansohn and col-
leagues,'7 of Feldberg and Vogt," and of others that the enzyme which
synthesizes ACh, choline acetylase (ChA), and that which hydrolyzes
ACh, acetylcholinesterase (ChE), are both present in the CNS. The
studies of Feldberg and Vogt' are classic and bear some scrutiny. They
found a curiously uneven distribution of ACh-synthesizing capacity in the
CNS. An interpretation of their findings was made by applying what is
known of the properties of cholinergic neurones in the peripheral nervous
system. Consideration was given, for example, to the following facts: that
a peripheral cholinergic fiber can synthesize ACh along its entire length;
that the magnitude of activity of the ACh-forming system in a tract is re-
lated to the number of cholinergic fibers contained in the tract; and that a
noncholinergic bundle is easily identified by its almost complete lack of
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ACh-synthesizing capacity. These workers concluded that in the CNS there
is often an alternation between cholinergic and non-cholinergic neurones
in both afferent and efferent pathways. This was most convincingly demon-
strated" in the optic pathway of the dog, where the retina was found to
be rich in ChA; the optic nerve, very low; the lateral geniculate bodies,
high again; and the visual area of the cortex, intermediate in activity.
Further analysis of the retina revealed that the first-order neurone was
noncholinergic, while the second-order neurone with its bipolar cell imping-
ing on the ganglionic layers was distinctly cholinergic.
There is substantiation of these findings in the work of Francis' and of
Anfinson,' who made use of a histochemical localization of ChE in the
cat's and cow's retina. They found a high concentration of the esterase in
the inner synaptic layer of the retina, indicating cholinergic transmission
from the bipolar cells to the ganglion cells, or that the second order
neurones are cholinergic. The absence of such evidence for ChE in the
outer synaptic layer is in agreement with the view of Feldberg and Vogt
that the first-order neurone is noncholinergic. It should be emphasized
here that findings arising from studies on the destructive enzyme may not
be as significant as those obtained from investigations of the synthesizing
enzyme because of the rather anomalous finding of ChE in the presynaptic
boutons termineaux of ganglia, instead of, as expected, it being in close
association with the postsynaptic receptor site (as at the motor end-plate).u
An alternating sequence of cholinergic and noncholinergic neurones simi-
lar to that in the optic pathway has also been found in the voluntary motor
pathway and elsewhere in the CNS.W The one criticism which one might
make of this work is that it was done at a time when acetyl-coenzyme A
had not yet been shown to be the active-acetate donor to the ChA system;
so Feldberg and Vogt used ATP to drive their ACh synthesis. Their
alternating sequence could conceivably represent an alternation of struc-
tures which can or cannot utilize ATP to form acetyl-CoA and ultimately
ACh. However, studies of the presence of endogenous ACh in various
brain structures bear out the uneven distribution idea; and it has already
been pointed out above that investigations of the distribution of ChE sub-
stantiate the alternating neurone concept in the optic pathway. Further-
more, a recent work by Hebb and Silver,4' taking into account that choline
acetylase activity is limited by a supply of acetylcoenzyme A, has largely
confirmed the results of Feldberg and Vogt.
In addition to fulfilling the first two criteria mentioned earlier, ACh,
when applied properly to the CNS, has pronounced central actions.
1. It causes a discharge of motor impulses leading to muscular con-
tractions.
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2. It alters the reflex excitability of the CNS.
3. Depending upon the size of the dose, it stimulates or depresses the
respiratory center.
4. It has an action on the centers of the autonomic nervous system
whereby changes in blood pressure, heart rate, and intestinal movements
are produced.
5. Injected into the region of the supra-optic nucleus, it causes a release
of antidiuretic hormone.
6. When injected into the ventricular system of the cat, the animal
undergoes something similar to an akinetic seizure.
All of these effects are produced by the direct application of ACh to
the brain or by injecting it into the vascular system, the latter being a
very inefficient way to administer it because the esterases of the blood
rapidly hydrolyze it, and because the blood-brain barrier bars it almost
completely from access to the CNS. There are, however, two other ways
to cause an increase in the local concentration of ACh in the brain.
1. Administration of any one of a large number of potent inhibitors of
ChE (such as physostigmine, di-isopropylfluoro ?hosphate, tetra-ethylpyro-
phosphate), most of which traverse the blood-brain barrier. Such drugs
have been shown to cause up to 200 per cent elevations in brain ACh.'
2. At least theoretically the administration of one of the precursors of
ACh would lead to an increase in its endogenous level. Choline can be
eliminated from consideration of brain ACh, because it cannot penetrate
the blood-brain barrier; but a precursor of choline, dimethylaminoethanol,
DMAE, is a tertiary amine and should enter the brain from its vascular
supply. Investigations in our laboratory, however, have failed to demon-
strate the conversion of unlabelled DMAE to brain ACh in vivo under a
number of conditions, or in vitro by rat brain slices, even when potential
sources of methyl groups were added to the medium.' Nevertheless,
DMAE has produced interesting pharmacological effects and behavioral
changes in animals and has led in humans to an elevation of mood and an
allaying of fatigue." It is at present under clinical trial as an antidepressive
drug in a number of psychiatric disorders.
The central effects observed with the various anticholinesterase drugs,
which allow the accumulation of endogenous ACh, represent a series of
observations highly pertinent to the question of whether ACh is a central
synaptic transmitter or not. There is a large number of such compounds,
most of which have been developed for purposes of chemical warfare. One
of the more potent and long-lasting of these, di-isopropylfluorophosphate
(DFP), has been rather extensively studied for its central actions and
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will serve here as a prototype for agents with similar irreversible ChE-
inhibiting properties. In man, DFP produces an emotional lability, rest-
lessness, tension, EEG changes and, in large enough doses, convulsions.
In general, these effects may be categorized as excitatory; and this is also
true in animals, whether intact, anesthetized, decerebrate, or spinal. In
large measure, the effects of DFP on the brain and on the spinal cord
are similar to those produced by ACh, but, of course, much more pro-
longed.'
Decisive in the argument relating the central effects of anticholinesterases
to ChE inhibition in the brain is the fact that although these compounds
are chemically dissimilar (physostigmine is a tertiary amine, neostigmine,
a quarternary ammonium compound, and DFP, a nonbasic organic phos-
phate ester), they all produce in low doses the same over-all effect. Since
ACh itself produces similar effects and is known to be present in brain,
the relationship is strengthened, as is the case for ACh's participation as
a central transmitter.
An interesting effect produced in animals by subconvulsive doses of
anticholinesterase compounds injected via the carotid artery is an easily
recognized and reproducible condition of forced circling movements. These
have been antagonized by atropine, and like certain other central changes
(e.g., those disclosed by EEG tracings) have been used as a technique for
studying centrally acting drugs in the cholinomimetic category. This allows
the emergence of one final point in the argument for ACh as a central
transmitter. Atropine is generally accepted as the classical antagonist of
the muscarinic actions of ACh in the autonomic nervous system. Thus,
if ACh is active as a central synaptic transmitter and if atropine can enter
the brain, one might expect atropine to exert interesting central effects,
related possibly to a central antagonism of ACh. It is known that atropine
will prevent the development of spike potentials by topical application of
ACh to the cerebral cortex,=M and that the intraventricular injection of
atropine in conjunction with ACh does not result in the spike discharges
usually seen when ACh is given alone by this route.'
If given in sufficiently large doses, atropine has definite central actions.
There is slowing and increased amplitude in the electrocorticogramM remi-
niscent of the barbiturates. And, like the barbiturates, it prevents the
appearance of the arousal reaction; but the situation is paradoxical, because
the animal is behaviorally awake and may even appear to be excited. This,
nevertheless, has been taken as evidence for a cholinergic mechanism in
the reticular activating system."
It is of interest that atropine has been of some clinical value in paralysis
agitans and in motion sickness, although certain synthetic compounds,
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somewhat analogous structurally to atropine, have been much more effec-
tive in these conditions. While the role of ACh in such disorders has not
been made clear, the clinical action of atropine may be looked upon as
presumptive evidence that ACh does play some role. Of significance in
this regard also is the production of toxic psychoses in humans who have
had an overdose of atropine. Recently, Abood and co-workerse have
reported powerful psychotogenic properties of a number of synthetic ana-
logs of atropine.
In recapitulation, it has been pointed out that ACh is present in the
CNS; that it is continually released and synthesized; that in minute
amounts it exerts a variety of central effects; and, what may be more per-
tinent, that a number of chemically diverse substances, which have one
property in common, the inhibition of ChE, all produce ACh-like central
effects; and that a peripheral inhibitor of ACh, atropine, and some of its
analogs have powerful central actions. These, it would seem, greatly
strengthen the theory that ACh is a central synaptic transmitter, regard-
less of what interpretation one places upon each single fact.
At this point, the question which has often been raised in the past (but
not so often recently) is whether ACh is the only central transmitter or
whether there is a whole family of central neuro-humors. Even in cho-
linergic mechanisms, ACh may be only one of several choline esters of
importance. In recent studies, urocanylcholine, acrylylcholine, and dimethyl-
acrylylcholine, and y-amino-butyrylcholine have all been found to occur
naturally and to exert potent effects. The evidence in favor of noncho-
linergic neurohumoral substances is accumulating rapidly, and is both sug-
gestive and provocative, but far from conclusive. Actually, it is not precise
to limit these to noncholinergic systems, because they could conceivably
serve as modulators of cholinergic systems as well.
CATECHOLAMINES AND 5-HYDROXYTRYPTAMINE (SEROTONIN; 5-H7)
In terms of the criteria mentioned earlier, two amines of recent study
have achieved consideration as central neurohumors of a magnitude almost
equal to that of ACh. These are norepinephrine (NE) and 5-HT. They
are both present and nonrandomly distributed in the brain (although the
presence of 5-HT in a neurone proper has not been demonstrated); there
are present in the nervous system rapidly active mechanisms for their syn-
thesis and destruction; and they both produce interesting, diffuse effects
when their levels in the brain are increased or decreased. In point of fact
there is a new school of thought (Osmond,' Woolley') which holds that
abnormalities in the metabolism of these amines is the underlying bio-
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chemical mechanism in the etiology of certain mental disorders. These
concepts rest upon tenuous and indirect evidence, to be sure, but they have
stimulated basic research in an area which has been in need of new and
imaginative approaches.
It is of interest that the distribution of these two amines in the CNS
is quite similar, both being localized in the gray matter of the mesencepha-
lon, diencephalon, and rhombencephalon. One quickly sees this parallelism
in Table 2, as well as almost complete lack of correlation with levels of ACh.
TABLE 2. LEVELS IN BRAIN OF DOG AND CAT OF NE, 5-HT, AND ACH RELATIVE
TO THE LEVEL IN THE HYPOTHALAMUS, EXPRESSED AS 100%*
Neural structure 5-HT NE ACh
Hypothalamus 100% 100% 100%
Amygdala 130 ... ...
Septal nuclei 123 ... ...
Pineal (Cow-ref. 35) 108 40 33
Area postrema 73 100 ...
Hippocampus 70 ... ...
Midbrain 61 36 ...
Floor 4th ventricle 38 26 ...
Superior colliculi 35 16 92
Spinal cord (Gray) 25 16 165
Medial thalamus 20 23 ...
Olfactory bulb 20 5 98
Cerebellum 3 6 10
References 62, 61 82 51
* These relative values were calculated from the following levels of the neuro-
humors in the hypothalamus (,ug./g. wet tissue): 5-HT in dog, 0.37, 2; NE in cat,
1.03"2; and ACh in cat, 1.8."1
Another series of findings which tend to link 5-HT and NE have to
do with alteration of the brain content of these two amines by certain
neuro-active drugs and precursors. For example, the potent tranquilizing
drug, reserpine, which is useful in the treatment of psychoses and psycho-
neuroses (as well as certain forms of hypertension) has been shown to
release NE and 5-HT from their storage sites in the brain (and from
other body depots).'"
' ' This property of reserpine is shared only by those
alkaloids of Rauwolfia which also exert a central tranquilizing action.'
It has been tempting, therefore, to ascribe the central actions of reserpine
and its active analogs to the release of NE and 5-HT. In fact, there has
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been some recent evidence'6 to show that the soporific action of reserpine
in mice can be abolished for a time or prevented by raising the brain levels
of HT and NE through the simple expedient of injecting their precursors,
5-hydroxytryptophan and 3, 4-dihydroxyphenylalanine (DOPA), respec-
tively.
This already complex situation is made more complicated by the find-
ings that other centrally acting drugs can influence brain levels of either
5-HT or NE (cf. Table 3).
TABLE 3. INFLUENCE OF SEVERAL DRUGS AND PRECURSORS ON BRAIN
CONTENT OF NE AND HT
Direction of change in brain content of:
Chemical agent HT NE Species-ref.
Apomorphine 0* Decrease Cat82
Morphine 0* Decrease Cat"
Reserpine Decrease Decrease Rabbite
Cat"
Anticonvulsants Increase ? Rate
Barbiturates Increase ? Rat'
Dog"
Iproniazid Increase Increase Rat!°
(in some species)
5-Hydroxytryptophan Increase ? Rate
"DOPA" ? Increase Mouse
* No change in rat's brain content.'
Two problems arise from a consideration of these data. The first is
whether there is a causal relationship between the change in neurohumoral
level observed with a given drug and the pharmacological action produced
by that drug. The other relates to such paradoxical situations as a high
brain level of 5-HT obtained in an animal depressed with a barbiturate or
excited with iproniazid or 5-hydroxytryptophan. This has been explained
by Brodie and Shore" on the theory that excess of 5-HT in the brain
counteracts its own action. Other possibilities exist, however, in the differ-
ential elevation of 5-HT levels in selected areas of the brain or in differ-
ential ratios of "bound" to free forms of 5-HT brought about by the drugs
in question." The crux of the matter finally may rest not in the changes
produced in the level of any single neuro-humor, but rather in the neces-
sary relatedness of these substances, one to the other. It would seem more
appropriate at this stage of our developing knowledge to visualize small
groups of related compounds which by mutual interaction would control
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the phenomena of neural excitation and inhibition, rather than to restrict
our thinking to unitary chemical schemes.
It is rather interesting to note that the precursors of NE and 5-HT,
dopamine and 5-hydroxytryptophan, respectively, can cause an increase
of from 200 per cent to 500 per cent in the brain level of the appropriate
famine in vivo. The same is true for inhibitors of monoamine oxidase, an
enzyme which can destroy NE and 5-HT (cf. the effect of iproniazid in
Table 3). However, lethal doses of potent inhibitors of cholinesterase, such
as DFP, produce at most, 150 per cent increase in brain ACh, while the
precursors of ACh, choline and dimethylaminoethanol, have no detectable
influence on brain levels of ACh in vivo. It would appear, therefore, that
mechanisms controlling brain levels of ACh are more efficient than those
controlling levels of 5-HT or NE.
Whether there is a causal relationship between the effects of the drugs
in Table 3 and the changes in brain NE and HT or not, it is a well-estab-
lished fact that exogenously produced changes in the concentrations of
these amines in the brain do elicit demonstrable central effects. These may
be summarized as follows:
1. NE and epinephrine (E) injected intracisternally, produce analgesia,
sleep and anesthesia, and a long-lasting hyperglycemia."
2. Similarly, Sherwood and Feldberg have found that small doses
(20-80y) of NE or E injected into the lateral ventricle of the cat cause a
condition resembling light nembutal anesthesia.
3. On the other hand, it has been showne that both NE and E can
produce arousal via the reticular activating system.
4. A rapidly induced sedation also follows the intraventricular admin-
istration of 5-HT in the cat' and in other species.'
5. By injecting either the catecholamines or 5-HT into the internal
carotid artery of the cat, Marazzi and co-workers have been able to study
their action on transmission in the transcallosal pathway.' They found
that 5-HT, NE, and E are all potent synaptic inhibitors in that order. A
similar synaptic inhibition can be achieved by injecting iproniazid ("Marsi-
lid"), a substance which spares 5-HT from destruction by monoamine
oxidase. These workers interpret their results as indicating that 5-HT
is a central synaptic inhibitory transmitter.
It is of interest in regard to the enzyme monoamine oxidase, that ipronia-
zid and other potent inhibitors of this enzyme recently have been found
to exert a stimulatory action on the CNS and to ameliorate the general
mental state and behavior of chronic apathetic schizophrenia and other
psychotic depressions.' These drugs have been called psychic energizers
or antidepressives because of this action. It has been tempting to ascribe
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the mechanism of such drugs to their monoamine oxidase-inhibiting activity
and the subsequent accumulation of 5-HT and NE in the CNS. But there
may be other related amines, not identified as yet in the CNS, which could
be oxidatively deaminated as well as 5-HT and NE by monoamine oxidase,
and therefore also could accumulate as a result of inhibition of the enzyme.
Udenfriend, e.g., has recently demonstrated the presence of tryptamine and
other amines in the urine of mammals after the administration of ipron-
iazid.' In addition, iproniazid and other monoamine oxidase inhibitors may
have other pharmacological actions. For example, it has been shown that
iproniazid can inhibit, to some extent, the reserpine-induced release of
5-HT from brain cells.'M
Finally, one might add that certain substances related structurally to
5-HT and certain substances antagonistic to the actions of 5-HT or NE
produce interesting central effects. Noteworthy among these are the fol-
lowing:
1. Bufotenine, the dimethyl analog of 5-HT, harmine, ibogaine, and
psilocybin are all naturally occurring indolic alkaloids which produce hal-
lucinations and behavioral changes in man. Their chemical relationship to
5-HT may be seen in Figure 1.
2. Lysergic acid diethylamide (LSD-25), another indole derivative
(Fig. 1), is a powerful 5-HT antagonist in some peripheral systems
(e.g., on the uterus) in one dosage range and mimics the action of 5-HT
in another. Minute oral doses of LSD-25 (75-100ly) characteristically pro-
duce bizarre mental aberrations, resembling schizophrenia, in humans.
3. Morphine and other narcotic analgesics (dihydromorphinone, metha-
done, pethidine, codeine, and ethylmorphine) have been shown to exert a
mild antagonistic action on the 5-HT-induced contraction of the guinea-
pig's ileum.' This effect parallels the analgesic potency of the drugs tested.
In this regard, it is interesting that reserpine, which depletes the brain of
5-HT and NE, can inhibit the analgesic action of morphine, while
iproniazid, which causes the accumulation of the two amines, can potenti-
ate morphine analgesia.'
4. Dibenamine and dibenzyline, both NE antagonists in the periphery,
have been used as tranquilizing drugs with mild success and are serving
as models for the development of new tranquilizers."
HISTAMINE
Other, less well-explored substances in the CNS are now under some
scrutiny. Histamine and substance P, a polypeptide, have been found
randomly distributed in the brain and present in the posterior roots. The
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possibility that histamine may be a transmitter of the polysynaptic reflex
arc has already been suggested.' The interesting point about histamine is
that it seems to increase in amount as one goes peripherally from the
brain (0.1 to 1 y/gm.) to the spinal cord (1 to 2 y/gm.) to the spinal
roots (4 to 11 y/gm.) out to certain postganglionic sympathetic nerves
HO Cf-1CH1C NHL H O HICH N(CH3)2
H H
5-HYDROXYTRYPTAMINE BUFOTENINE
(5-HT, SEROTONIN)
CH3O
CH3 0 CHO( g HCH32C CI1~~O H33
HARMINE IBOGAINE
O=C-N(C,H5), S OH
OCH1N
H H
LYSERGIC ACID DIETHYLAMIDE PSILOCYBIN
(LSD-25)
FIG. 1.
(as high as 100 y/gm. in the splenic nerves of the ox=). This distribution
may be related to the distribution of mast cells, which are few in the CNS
but plentiful in the perineurium and endoneurium of peripheral nerves.'
However, studies on desheathed nerves and on nerves with few mast cells
and high histamine content (like the vagus) indicate that not all neural
histamine is contained in mast cells.
Some areas of the brain, moreover, are relatively rich in histamine:
optic nerves,' hypothalamus,' and the pineal gland.8' In addition, histamine
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does have some central excitatory action, and small doses cause a pro-
nounced increase in the electrical activity of the cerebellum.t' It has also
been shown that histamine will stimulate the superior cervical ganglion
and the central cell stations of the sympathetic system."
One of the major problems to be reckoned with in assigning a neuro-
humoral role to histamine is concerned with the mechanisms for the bio-
formation and biotransformation of the amine in nervous tissue. These
mechanisms are poorly explored in the organism as a whole although
Werle has shown that some nerves (vagus, pre- and postganglionic sym-
pathetic fibers) can make histamine by decarboxylation of histidine.8' The
content of histamine in various neural structures of the cerebrospinal axis,
and the histidine decarboxylase and histaminase activity of these areas
need to be systematically investigated before further emphasis can be placed
on histamine as a neurohumor. The fact that histamine is distributed uni-
formly along peripheral nerve fibers and not concentrated in their terminals
makes it unlikely that histamine is liberated as a mediator of nerve im-
pulses. West views histamine rather as a line of defense against injury
possessed by certain nerves.'
The possibility exists that histamine is a precursor of another active
material which may play some role in nerve function. It has been observed
that histamine-like activity in extracts of the sympathetic trunk from the
ox may be inactivated by treatment with alkali, which ordinarily does not
destroy histamine.'M The recent finding that histamine is N-methylated by
imidazole N-methyl transferase of mouse liver is also of some significance
in this regard,' because earlier it had been shown that N-methyl histamine
is a good substrate of monoamine oxidase and can be spared from break-
down to 1-methyl-imidazole-4-acetic acid by iproniazid.'
It is now well established that various antagonists (in peripheral sys-
tems) of histamine have interesting and useful central actions; but the
relationship between effects on the nervous system and a central antagonism
of histamine is entirely presumptive. A number of these drugs have been
used effectively as anti-emetic agents, as hypnotics and sedatives, and, more
recently, as tranquilizers (e.g., hydroxyzine). In evaluating such actions
in terms of neurohumoral antagonism, it is well to remember that the so-
called antihistamine drugs are often mild antagonists of ACh or NE or
both.
SUBSTANCE P
The polypeptide, substance P, occurs in appreciable concentration in the
brain with highest values in the area postrema, hypothalamus, basal gang-
lia, and gray matter of the medulla spinalis.' It has also been found in
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the retina of the cow and dog. In the dorsal roots, Hellauer and Umrath
have found a vasodilator factor to which they have ascribed a transmitter
function.' Whether this is the same as substance P which also occurs in
this site, has not yet been ascertained. Nevertheless, Kopera and Lazarini
consider substance P to act as a chemical mediator of nerve impulses in
the CNS."
Little is known about the mechanisms of bioformation and destruction
of substance P either in the CNS or elsewhere, although presumably the
usual pathways for peptide synthesis and degradation are involved. How-
ever, it is known that administration of the material does evoke certain
central effects. Intracisternal or intraventricular injections of small doses
of a highly purified preparation elicit stimulation of respiratory frequency
and amplitude in cats and rabbits. Injected into the lateral ventricle, sub-
stance P produces a variety of signs marked by a general inhibition of
spontaneous activity.TM Moreover, changes in the EEG of the cortex (de-
creased amplitude, increased frequency) and of the hippocampus of the
rabbit by the intracarotid administration of small amounts of substance P
have been interpreted to indicate an influence on activating systems.' It
is rather intriguing that the distribution of substance P is similar to that
of 5-HT and NE except for its concentration in dorsal roots. In view
of their concentration in area postema, hypothalamus, and medial thalamus,
all three substances are considered to have an "equally good (or bad)
claim to reticular function."'
GAMMA-AMINOBUTYRIC ACID
One of the most intriguing of recent developments in neurochemistry
has been the elucidation of the presence in brain of a relatively simple
amino acid, y-aminobutyric acid (GABA), and the demonstration of its
inhibitory synaptic activity. A few years ago Florey had reported upon
the inhibitory activity of extracts of brain and spinal cord on the genera-
tion of impulses by the stretch receptor neurone of the crayfish.' The
agent (or agents) responsible for this action was called Factor I; and
only recently a major component of Factor I was identified as GABA.7
It is remarkable that Hayashi and Nagai, studying a number of related
compounds for anticonvulsant activity, chose y-amino-/3-hydroxybutyric
acid as a potential central inhibitory substance.
The presence of GABA in brain has been known since 1950; until re-
cently it has been considered mainly from the point of view of its role in
intermediary metabolism. It was shown that GABA is produced in brain
from glutamic acid under the catalysis of a glutamic acid decarboxylase,
which requires pyridoxal phosphate as a co-factor.' The dissipation of
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GABA depends mainly upon its transamination with a-ketogluturate to
produce glutamic acid and succinic semialdehyde.' This latter substance
may enter the tricarboxylic acid cycle and thus be utilized for energy pro-
duction. However, GABA itself has been shown recently to support oxygen
utilization by slices of the cat's cerebral cortex.'
Uniquely high quantities of GABA (approximately 400 y/gm.) have
been found in an easily extractable form in the CNS of representative
species of vertebrates but not in other tissues. The possible function and
importance of this substance in the CNS, however, is still a matter of spec-
ulation. The depressant action of GABA when applied to the cortex of
normal animals and the anticonvulsant activity of GABA in mice has
focused attention on a possible role which it may play in seizure and anti-
seizure systems in the brain. Convulsant hydrazides, such as thiosemi-
carbazide, which inactivate pyridoxal, have been shown to produce a de-
crease in the activity of glutamic acid decarboxylase and in the content of
GABA in the brains of rats and to decrease the rate of formation of GABA
from glutamic acid in vivo in mice."7"' Yet it has recently been reported
that there is no correlation between seizure-susceptibility of certain areas
of the brain and their content of GABA.' It may be premature to impli-
cate only GABA in seizures produced by thiosemicarbazide and other
pyridoxal-inactivating compounds, because it is well-established that pyri-
doxal is a co-factor for the decarboxylases which form 5-HT and dopamine
(leading to the formation of NE). It is possible, therefore, that these
amines are equally important in the problem of seizures. Furthermore,
semicarbazides havebeen shown also to inhibithistaminase.'
Other workers have shown that topically applied GABA reverses sur-
face negative postsynaptic potentials of the apical dendrites evoked by
various stimuli in the cerebral cortex of unanesthetized cats."' This effect
is probably restricted to the surface layers of the cortex.' Since it had
been proposed that electrocortical arousal is associated with the generation
of inhibitory postsynaptic potentials in the apical dendrites of the cortex,
Magoun and his colleagues looked for a role for GABA in such arousal
butconcluded that it had none.'
Thus, it is still problematic whether GABA is concerned with the regu-
lation of physiological activity of the brain and other nervous structures.
The very high levels of this amino acid in the central gray matter might
represent a store of a precursor of an unknown, active metabolite. In this
regard, the finding in dog's brain of a substance identified as y-amino-
butyrylcholine4 would appear to be highly significant. The proof of identity
of this ester was far from rigorous, however; and the relatively long sojourn
of the compound in the organism due to an absence of esteratic cleavage,
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as shown in human blood, in cat's blood, and in mouse brain,7 would
detract from the possibility of its playing an important role in neurophysi-
ology.
Events in the central synapses are characterized by rapid firing rates
(up to 1,000 per second have been described) and relative transience in
course. In this light, none of the substances mentioned above, with the
exception of ACh, is acceptable as a synaptic transmitter, because of their
relatively prolonged action. It might be argued, however, that transience
of action is not as essential to the functioning of an inhibitory transmitter
as it is to a facilitatory one. In any event, one must attach some importance
to the fact that these substances do exist in the CNS in interesting dis-
tributional patterns.
It is well accepted that the CNS is incredibly complex functionally and
anatomically. Therefore, it does not seem reasonable to expect it to be
so simple chemically as to be provided with a single universal transmitter.
It is most likely that there exists a whole family of transmitters and a
number of neuroregulators which may modulate the reactivity of neurones
to these transmitters.
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